Variation in health plan coverage of ESAs for anemia due to chronic kidney disease

BACKGROUND: Because health plans each issue their own policies, drug coverage can vary. This variation can result in patients having unequal access to treatment. In this study, we evaluate commercial health plans’ coverage policies for erythropoiesis-stimulating agents (ESAs) for patients with anemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Margaretos, NikoLetta M, Panzer, Ari D, Lai, Rachel C, Sanon, Myrlene, Michalopoulos, Efstathios, Redmond, Ann-Marie, Moghadam, Reza, Chambers, James D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391084/
https://www.ncbi.nlm.nih.gov/pubmed/34464213
http://dx.doi.org/10.18553/jmcp.2021.27.9.1221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391084/
https://www.ncbi.nlm.nih.gov/pubmed/34464213
http://dx.doi.org/10.18553/jmcp.2021.27.9.1221

Ejemplares similares